<p>Pictet Asset Management Holding SA 在最近向美国证券交易委员会（SEC）披露的文件中表示，其在达维塔公司（NYSE:DVA - 免费报告）的持股在第四季度减少了 69.2%。该基金在此期间出售了 17,018 股后，持有 7,558 股达维塔的股票。根据其最近的 SEC 文件，Pictet Asset Management Holding SA 在达维塔的持股价值为 859,000 美元。</p>
<ul>
<li>伯克希尔哈撒韦在巴菲特最后一个季度的表现</li>
</ul>
<p>其他大型投资者最近也调整了对该公司的持股。Elevation Wealth Partners LLC 在第四季度将其在达维塔的股份增加了 147.3%。Elevation Wealth Partners LLC 目前持有 277 股达维塔的股票，价值 31,000 美元，此前在上个季度又增持了 165 股。加拿大养老金计划投资委员会在第二季度购买了达维塔的新股份，价值 43,000 美元。iSAM Funds UK Ltd 在第三季度购买了达维塔的新股份，价值 46,000 美元。Stance Capital LLC 在第三季度购买了达维塔的新股份，价值 47,000 美元。最后，Smartleaf Asset Management LLC 在第三季度将其在达维塔的股份增加了 34.9%。Smartleaf Asset Management LLC 目前持有 452 股达维塔的股票，价值 59,000 美元，此前在上个季度又增持了 117 股。机构投资者持有该公司 90.12% 的股票。</p>
<h2>华尔街分析师预测增长</h2>
<p>DVA 成为多份分析师报告的主题。Zacks Research 在 4 月 6 日的研究报告中将达维塔的股票评级从 “强力买入” 下调至 “持有”。瑞银集团在 2 月 4 日的研究报告中将达维塔的目标价从 186.00 美元上调至 190.00 美元，并给予该股票 “买入” 评级。德意志银行在周三的研究报告中将达维塔的评级从 “持有” 上调至 “买入”，并将该股票的目标价从 126.00 美元上调至 220.00 美元。Wall Street Zen 在 2 月 21 日的研究报告中将达维塔的评级从 “持有” 上调至 “买入”。最后，TD Cowen 在 2 月 3 日的研究报告中重申了对达维塔的 “持有” 评级。两位分析师给予该股票 “买入” 评级，五位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，达维塔目前的共识评级为 “持有”，平均目标价为 166.50 美元。</p>
<ul>
<li>巴菲特最新的投资组合变动，以及另一只秘密股票</li>
</ul>
<p><strong>查看我们对达维塔的最新分析</strong></p>
<h2>达维塔新闻摘要</h2>
<p>以下是本周影响达维塔的主要新闻：</p>
<ul>
<li>积极情绪：第一季度超预期：达维塔报告调整后的每股收益为 2.87 美元，收入为 34.2 亿美元，超出市场共识，并显示出同比收入增长和利润率扩张——这是推动股价上涨的关键因素。达维塔 2026 年第一季度业绩</li>
<li>积极情绪：指引上调：管理层将 2026 财年调整后的每股收益指引上调至 14.100–15.200 的区间，略高于/与市场预期一致——这降低了全年利润的不确定性，并支持市盈率扩张。达维塔上调年度利润预测</li>
<li>积极情绪：资本回报和投资者信心：公司披露了持续的股票回购（在本季度的回购和到 5 月 5 日的额外回购），这支持了每股收益和投资者情绪；异常的期权活动（大量看涨期权交易）表明了看涨的市场定位。Quiver Quantitative 分析</li>
<li>中性情绪：投资者接触——管理层参与美银健康会议（5 月 12 日）为投资者提供了另一个获取指引和问答的场所；根据评论可能进一步影响情绪。达维塔将参加美银 2026 年健康护理会议</li>
<li>中性情绪：分析师活动：德意志银行重申/给予 “买入” 评级，并设定更高的 220 美元目标，而其他机构的看法各异——积极的分析师评论可以强化涨幅，但覆盖情况不一。Quiver Quantitative 分析</li>
<li>消极情绪：机构/内部人士抛售：大型机构减持和显著的内部人士销售（包括与伯克希尔相关的过去销售）如果持续将成为潜在的阻力。Quiver Quantitative 分析</li>
<li>消极情绪：盈利能力指标混合：尽管利润率改善，但一些指标（报告的历史负净资产收益率）和对报销动态的依赖仍然是长期风险，投资者可能在初次上涨后重新评估。MarketBeat DVA 概况</li>
</ul>
<h2>达维塔股价上涨 22.6%</h2>
<ul>
<li>华尔街对这两只上半年赢家持谨慎态度</li>
</ul>
<p>NYSE:DVA 周四开盘价为 192.49 美元。该股票的市值为 128.6 亿美元，市盈率为 17.86，PEG 比率为 0.55，贝塔值为 0.84。该公司有 50 日简单移动平均线为 152.12 美元，200 日简单移动平均线为 132.20 美元。达维塔的 12 个月低点为 101.00 美元，12 个月高点为 194.29 美元。</p>
<p>达维塔（NYSE:DVA - 获取免费报告）在 5 月 5 日星期二发布了季度财报。该公司报告季度每股收益为 2.87 美元，超出分析师的共识预期 2.33 美元，超出 0.54 美元。该业务在本季度的收入为 34.2 亿美元，而分析师的预期为 33.6 亿美元。达维塔的净利润率为 5.65%，负净资产收益率为 325.68%。该业务的季度收入同比增长 6.0%。去年同期，该公司每股收益为 2.00 美元。达维塔已将其 2026 财年的指引设定为 14.100-15.200 每股收益。股票分析师预测达维塔将在当前财年发布 14.16 美元的每股收益。</p>
<h2>达维塔简介</h2>
<p>（免费报告）</p>
<p>达维塔公司（DaVita Inc，NYSE: DVA）是领先的肾脏护理服务提供商，专注于为慢性肾衰竭和终末期肾病患者管理和运营门诊透析中心。公司总部位于科罗拉多州丹佛，提供全面的治疗方案，包括中心血液透析、腹膜透析和家庭透析治疗。除了核心的透析服务外，达维塔还提供患者教育、营养咨询、血管通路管理及相关实验室服务，以支持肾脏健康和整体患者福祉。</p>
<p>自 1990 年代中期通过临床管理服务的分拆成立以来，达维塔通过有机增长以及战略合作和收购不断扩展。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过达维塔</li>
</ul>
<p><strong>想看看其他对 DVA 感兴趣的对冲基金持有什么？</strong> 请访问 HoldingsChannel.com，获取达维塔公司（NYSE:DVA - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURWQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURWQQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 到达维塔吗？</h2>
<p>在考虑达维塔之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而达维塔并不在名单上。</p>
<p>虽然达维塔目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

达维塔保健

<p>Pictet Asset Management Holding SA 已将其在 DaVita Inc. 的持股比例减少了 69.2%，在第四季度出售了 17,018 股，剩余 7,558 股，价值 859,000 美元。其他投资者，包括 Elevation Wealth Partners 和加拿大养老金计划投资委员会，也调整了他们的持股。DaVita 的股票获得了分析师的褒贬不一的评级，普遍评级为 “持有”，目标价格为 166.50 美元。该公司报告了强劲的第一季度业绩，提高了 2026 财年的每股收益指引，但面临机构抛售和盈利指标不一的挑战</p>

<p>Pictet Asset Management Holding SA lowered its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 69.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 7,558 shares of the company's stock after selling 17,018 shares during the period. Pictet Asset Management Holding SA's holdings in DaVita were worth $859,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Pictet Asset Management Holding SA 在最近向美国证券交易委员会（SEC）披露的文件中表示，其在达维塔公司（NYSE:DVA - 免费报告）的持股在第四季度减少了 69.2%。该基金在此期间出售了 17,018 股后，持有 7,558 股达维塔的股票。根据其最近的 SEC 文件，Pictet Asset Management Holding SA 在达维塔的持股价值为 859,000 美元。</p>
</div><ul>
<li>How Berkshire Hathaway Performed During Buffett's Final Quarter</li>
</ul>
<div class="lb-trans"><ul>
<li>伯克希尔哈撒韦在巴菲特最后一个季度的表现</li>
</ul>
</div><p>Other large investors have also recently modified their holdings of the company. Elevation Wealth Partners LLC raised its stake in shares of DaVita by 147.3% during the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company's stock valued at $31,000 after acquiring an additional 165 shares during the last quarter. Canada Pension Plan Investment Board bought a new position in shares of DaVita during the second quarter valued at $43,000. iSAM Funds UK Ltd bought a new position in DaVita during the third quarter worth $46,000. Stance Capital LLC bought a new position in DaVita during the third quarter worth $47,000. Finally, Smartleaf Asset Management LLC raised its stake in DaVita by 34.9% during the third quarter. Smartleaf Asset Management LLC now owns 452 shares of the company's stock worth $59,000 after buying an additional 117 shares during the last quarter. Institutional investors own 90.12% of the company's stock.</p>
<div class="lb-trans"><p>其他大型投资者最近也调整了对该公司的持股。Elevation Wealth Partners LLC 在第四季度将其在达维塔的股份增加了 147.3%。Elevation Wealth Partners LLC 目前持有 277 股达维塔的股票，价值 31,000 美元，此前在上个季度又增持了 165 股。加拿大养老金计划投资委员会在第二季度购买了达维塔的新股份，价值 43,000 美元。iSAM Funds UK Ltd 在第三季度购买了达维塔的新股份，价值 46,000 美元。Stance Capital LLC 在第三季度购买了达维塔的新股份，价值 47,000 美元。最后，Smartleaf Asset Management LLC 在第三季度将其在达维塔的股份增加了 34.9%。Smartleaf Asset Management LLC 目前持有 452 股达维塔的股票，价值 59,000 美元，此前在上个季度又增持了 117 股。机构投资者持有该公司 90.12% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>DVA has been the subject of a number of analyst reports. Zacks Research downgraded shares of DaVita from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, April 6th. UBS Group lifted their target price on shares of DaVita from $186.00 to $190.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, February 4th. Deutsche Bank Aktiengesellschaft raised shares of DaVita from a &#34;hold&#34; rating to a &#34;buy&#34; rating and lifted their target price for the stock from $126.00 to $220.00 in a research note on Wednesday. Wall Street Zen raised shares of DaVita from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, February 21st. Finally, TD Cowen reissued a &#34;hold&#34; rating on shares of DaVita in a research note on Tuesday, February 3rd. Two analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, DaVita presently has a consensus rating of &#34;Hold&#34; and an average price target of $166.50.</p>
<div class="lb-trans"><p>DVA 成为多份分析师报告的主题。Zacks Research 在 4 月 6 日的研究报告中将达维塔的股票评级从 “强力买入” 下调至 “持有”。瑞银集团在 2 月 4 日的研究报告中将达维塔的目标价从 186.00 美元上调至 190.00 美元，并给予该股票 “买入” 评级。德意志银行在周三的研究报告中将达维塔的评级从 “持有” 上调至 “买入”，并将该股票的目标价从 126.00 美元上调至 220.00 美元。Wall Street Zen 在 2 月 21 日的研究报告中将达维塔的评级从 “持有” 上调至 “买入”。最后，TD Cowen 在 2 月 3 日的研究报告中重申了对达维塔的 “持有” 评级。两位分析师给予该股票 “买入” 评级，五位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，达维塔目前的共识评级为 “持有”，平均目标价为 166.50 美元。</p>
</div><ul>
<li>Buffett's Latest Portfolio Moves, and Another Secret Stock</li>
</ul>
<div class="lb-trans"><ul>
<li>巴菲特最新的投资组合变动，以及另一只秘密股票</li>
</ul>
</div><p><strong>View Our Latest Analysis on DaVita</strong></p>
<div class="lb-trans"><p><strong>查看我们对达维塔的最新分析</strong></p>
</div><h2>DaVita News Summary</h2>
<div class="lb-trans"><h2>达维塔新闻摘要</h2>
</div><p>Here are the key news stories impacting DaVita this week:</p>
<div class="lb-trans"><p>以下是本周影响达维塔的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Q1 beat: DaVita reported adjusted EPS of $2.87 and revenue of $3.42B, topping consensus and showing year‑over‑year revenue growth and margin expansion — a key driver of the rally. DaVita Inc. 1st Quarter 2026 Results</li>
<li>Positive Sentiment: Guidance raise: Management lifted FY2026 adjusted EPS guidance to a range of 14.100–15.200, slightly above/consistent with street expectations — this reduces uncertainty on full‑year profits and supports multiple expansion. DaVita lifts annual profit forecast</li>
<li>Positive Sentiment: Capital returns and investor confidence: Company disclosed ongoing buybacks (repurchases during the quarter and additional repurchases through May 5), which supports EPS and investor sentiment; unusual option activity (large call volume) indicates bullish positioning. Quiver Quantitative analysis</li>
<li>Neutral Sentiment: Investor access — management participation at BofA Healthcare Conference (May 12) gives investors another venue for guidance color and Q&amp;A; could further influence sentiment depending on commentary. DaVita to Participate in BofA 2026 Health Care Conference</li>
<li>Neutral Sentiment: Analyst activity: Deutsche Bank reiterated/issued a Buy and set a higher $220 target while other houses vary — positive analyst commentary can reinforce gains but coverage is mixed. Quiver Quantitative analysis</li>
<li>Negative Sentiment: Institutional/insider selling: Large institutional reductions and notable insider sales (including past sales by Berkshire-related positions) are a potential headwind if sustained. Quiver Quantitative analysis</li>
<li>Negative Sentiment: Profitability metrics mixed: despite margin improvement, some metrics (reported negative historical ROE) and reliance on reimbursement dynamics remain longer‑term risks investors may reassess after the initial rally. MarketBeat DVA profile</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：第一季度超预期：达维塔报告调整后的每股收益为 2.87 美元，收入为 34.2 亿美元，超出市场共识，并显示出同比收入增长和利润率扩张——这是推动股价上涨的关键因素。达维塔 2026 年第一季度业绩</li>
<li>积极情绪：指引上调：管理层将 2026 财年调整后的每股收益指引上调至 14.100–15.200 的区间，略高于/与市场预期一致——这降低了全年利润的不确定性，并支持市盈率扩张。达维塔上调年度利润预测</li>
<li>积极情绪：资本回报和投资者信心：公司披露了持续的股票回购（在本季度的回购和到 5 月 5 日的额外回购），这支持了每股收益和投资者情绪；异常的期权活动（大量看涨期权交易）表明了看涨的市场定位。Quiver Quantitative 分析</li>
<li>中性情绪：投资者接触——管理层参与美银健康会议（5 月 12 日）为投资者提供了另一个获取指引和问答的场所；根据评论可能进一步影响情绪。达维塔将参加美银 2026 年健康护理会议</li>
<li>中性情绪：分析师活动：德意志银行重申/给予 “买入” 评级，并设定更高的 220 美元目标，而其他机构的看法各异——积极的分析师评论可以强化涨幅，但覆盖情况不一。Quiver Quantitative 分析</li>
<li>消极情绪：机构/内部人士抛售：大型机构减持和显著的内部人士销售（包括与伯克希尔相关的过去销售）如果持续将成为潜在的阻力。Quiver Quantitative 分析</li>
<li>消极情绪：盈利能力指标混合：尽管利润率改善，但一些指标（报告的历史负净资产收益率）和对报销动态的依赖仍然是长期风险，投资者可能在初次上涨后重新评估。MarketBeat DVA 概况</li>
</ul>
</div><h2>DaVita Trading Up 22.6%</h2>
<div class="lb-trans"><h2>达维塔股价上涨 22.6%</h2>
</div><ul>
<li>Wall Street Is Cautious on These 2 First Half Winners</li>
</ul>
<div class="lb-trans"><ul>
<li>华尔街对这两只上半年赢家持谨慎态度</li>
</ul>
</div><p>NYSE:DVA opened at $192.49 on Thursday. The stock has a market capitalization of $12.86 billion, a price-to-earnings ratio of 17.86, a PEG ratio of 0.55 and a beta of 0.84. The firm has a fifty day simple moving average of $152.12 and a two-hundred day simple moving average of $132.20. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $194.29.</p>
<div class="lb-trans"><p>NYSE:DVA 周四开盘价为 192.49 美元。该股票的市值为 128.6 亿美元，市盈率为 17.86，PEG 比率为 0.55，贝塔值为 0.84。该公司有 50 日简单移动平均线为 152.12 美元，200 日简单移动平均线为 132.20 美元。达维塔的 12 个月低点为 101.00 美元，12 个月高点为 194.29 美元。</p>
</div><p>DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, topping analysts' consensus estimates of $2.33 by $0.54. The business had revenue of $3.42 billion during the quarter, compared to analysts' expectations of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 325.68%. The business's quarterly revenue was up 6.0% on a year-over-year basis. During the same period last year, the company posted $2.00 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities analysts predict that DaVita Inc. will post 14.16 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>达维塔（NYSE:DVA - 获取免费报告）在 5 月 5 日星期二发布了季度财报。该公司报告季度每股收益为 2.87 美元，超出分析师的共识预期 2.33 美元，超出 0.54 美元。该业务在本季度的收入为 34.2 亿美元，而分析师的预期为 33.6 亿美元。达维塔的净利润率为 5.65%，负净资产收益率为 325.68%。该业务的季度收入同比增长 6.0%。去年同期，该公司每股收益为 2.00 美元。达维塔已将其 2026 财年的指引设定为 14.100-15.200 每股收益。股票分析师预测达维塔将在当前财年发布 14.16 美元的每股收益。</p>
</div><h2>DaVita Profile</h2>
<div class="lb-trans"><h2>达维塔简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>DaVita Inc NYSE: DVA is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.</p>
<div class="lb-trans"><p>达维塔公司（DaVita Inc，NYSE: DVA）是领先的肾脏护理服务提供商，专注于为慢性肾衰竭和终末期肾病患者管理和运营门诊透析中心。公司总部位于科罗拉多州丹佛，提供全面的治疗方案，包括中心血液透析、腹膜透析和家庭透析治疗。除了核心的透析服务外，达维塔还提供患者教育、营养咨询、血管通路管理及相关实验室服务，以支持肾脏健康和整体患者福祉。</p>
</div><p>Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.</p>
<div class="lb-trans"><p>自 1990 年代中期通过临床管理服务的分拆成立以来，达维塔通过有机增长以及战略合作和收购不断扩展。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than DaVita</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过达维塔</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding DVA?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 DVA 感兴趣的对冲基金持有什么？</strong> 请访问 HoldingsChannel.com，获取达维塔公司（NYSE:DVA - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURWQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=DVA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in DaVita Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 到达维塔吗？</h2>
</div><p>Before you consider DaVita, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑达维塔之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而达维塔并不在名单上。</p>
</div><p>While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然达维塔目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Pictet Asset Management Holding SA Sells 17,018 Shares of DaVita Inc. $DVA

Market Beat

伯克希尔哈撒韦-A

伯克希尔哈撒韦-B

瑞银集团

德意志银行

美国银行

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

百达资产管理控股公司出售了 17,018 股达维塔公司（DaVita Inc.）的股票 $DVA